-
公开(公告)号：US20160102298A1
公开(公告)日：2016-04-14
申请号：US14970832
申请日：2015-12-16
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Tibor Czabany , Alfred Engel , Michael Greif , Christine Jung , Christiane Luley , Sebastian Malik , Rainer Mueller , Bernd Nidetzky , Doris Ribitsch , Katharina Schmoelzer , Helmut Schwab , Harald Sobek , Bernhard Suppmann , Marco Thomann , Sabine Zitzenbacher
IPC: C12N9/10
CPC classification number: C12N9/1081 , C12N9/1048 , C12Y204/99001
Abstract: The present disclosure is directed to glycosyltransferase variants having N-terminal truncation deletions. Contrary to previous findings certain truncations comprising the conserved amino acid motif (“QVWxKDS”) were found to be compatible with glycosyltransferase enzymatic activity, particularly in a human sialyltransferase (hST6Gal-I). Thus, disclosed are variants of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variants of mammalian glycosyltransferase and use thereof, particularly for sialylating terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins.
Abstract translation: 本公开涉及具有N-末端截短缺失的糖基转移酶变体。 与之前的发现相反，发现包含保守氨基酸基序（“QVWxKDS”）的某些截短与糖基转移酶酶活性相容，特别是在人唾液酸转移酶（hST6Gal-1）中。 因此，公开了哺乳动物糖基转移酶的变体，编码它们的核酸，用于重组产生哺乳动物糖基转移酶变体的方法和手段及其用途，特别是用作糖蛋白的部分的聚糖末端受体基团，例如免疫球蛋白。
-
公开(公告)号：US20160032260A1
公开(公告)日：2016-02-04
申请号：US14885727
申请日：2015-10-16
Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
Inventor： Harald Sobek , Johann-Peter Thalhofer , Rainer Mueller , Manfred Schmidt , Michael Greif , Armin Ruf , Christian Rudolph
IPC: C12N9/12
CPC classification number: C12N9/1247 , C12P19/34 , C12Y207/07006
Abstract: The present invention provides improved variants of T7 RNA polymerase by introducing novel mutations which lead to improved thermostability of the enzyme. According to the invention, amino acid substitutions at the positions Val426, Ser633, Val650, Thr654, Ala702, Val795, and combinations thereof are advantageous.
-
公开(公告)号：US09481902B2
公开(公告)日：2016-11-01
申请号：US14970734
申请日：2015-12-16
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Tibor Czabany , Alfred Engel , Michael Greif , Christine Jung , Christiane Luley , Sebastian Malik , Rainer Mueller , Bernd Nidetzky , Doris Ribitsch , Katharina Schmoelzer , Helmut Schwab , Harald Sobek , Bernhard Suppmann , Marco Thomann , Sabine Zitzenbacher
CPC classification number: C12P21/005 , C07K16/00 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C12N9/1081 , C12P19/18 , C12Y204/99001
Abstract: The present disclosure is directed to the use of certain glycosyltransferase variants having N-terminal truncation deletions. It was found that the combination of two different truncation variants of human β-galactoside-α-2,6-sialyltransferase I (hST6Gal-I) exhibited different specific sialyltransferase enzymatic activities. In one example, under conditions wherein the first variant Δ89 hST6Gal-I catalyzed formation of bi-sialylated target molecules the second variant Δ108 hST6Gal-I catalyzed formation of mono-sialylated target molecules. Thus, disclosed are variants of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variants of mammalian glycosyltransferase and use thereof, particularly for sialylating in a quantitatively controlled manner terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins.
Abstract translation: 本公开涉及使用具有N-末端截短缺失的某些糖基转移酶变体。 发现人β-半乳糖苷-α-2,6-唾液酸转移酶I（hST6Gal-1）的两种不同截短变体的组合表现出不同的特异性唾液酸转移酶酶活性。 在一个实例中，在第一变体Δ89hST6Gal-1催化双唾液酸化靶分子的形成的条件下，第二变体Δ108hST6Gal-1催化单唾液酸化靶分子的形成。 因此，公开了哺乳动物糖基转移酶的变体，编码它们的核酸，用于重组产生哺乳动物糖基转移酶变体的方法和手段及其用途，特别是以定量控制的方式唾液酸化作为糖蛋白部分的聚糖部分的末端受体基团，例如 免疫球蛋白。
-
公开(公告)号：US20160076068A1
公开(公告)日：2016-03-17
申请号：US14950443
申请日：2015-11-24
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Alfred Engel , Michael Greif , Christine Jung , Sebastian Malik , Rainer Mueller , Harald Sobek , Bernhard Suppmann , Marco Thomann
CPC classification number: C12P19/18 , C12N9/1081 , C12P19/02 , C12P19/44 , C12P21/005
Abstract: The present disclosure is directed to the use of certain glycosyltransferase variants having N-terminal truncation deletions. Contrary to previous findings certain truncations were found to exhibit sialidase enzymatic activity, particularly a variant of human sialyltransferase (hST6Gal-I) with a truncation deletion involving the first 89 N-terminal amino acids of the respective wild-type polypeptide. A fundamental finding documented in the present disclosure is that there exists a variant of this enzyme which is capable of catalyzing transfer of a glycosyl moiety as well as hydrolysis thereof. Thus, disclosed is a specific exemplary variant of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variant of mammalian glycosyltransferase and use thereof, particularly for sialylating in a quantitatively controlled manner terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins.
Abstract translation: 本公开涉及使用具有N-末端截短缺失的某些糖基转移酶变体。 发现某些截短表现出唾液酸酶酶活性，特别是具有涉及相应野生型多肽的前89个N-末端氨基酸的截短缺失的人唾液酸转移酶（hST6Gal-1）的变体。 在本公开文献中记载的基本发现是存在能够催化糖基部分的转移以及其水解的酶的变体。 因此，公开了哺乳动物糖基转移酶的特定示例性变体，编码哺乳动物糖基转移酶的核酸，用于重组产生哺乳动物糖基转移酶变体的方法和手段及其用途，特别是以定量控制的方式唾液酸化作为部分的聚糖部分的末端受体基团 糖蛋白如免疫球蛋白。
-
5.发明申请公开(公告)号：US20160010069A1
公开(公告)日：2016-01-14
申请号：US14872392
申请日：2015-10-01
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Michael Greif , Christian Rudolph , Manfred Schmidt , Harald Sobek , Johann-Peter Thalhofer
IPC: C12N9/12
CPC classification number: C12N9/1247 , C12Y207/07006
Abstract: The present disclosure provide novel variants of T7 RNA polymerase. Embodiments of T7 variants, according to the instant invention, include a Cysteine-Serine substitution on position 723 of the amino acid sequence of the T7 polypeptide. Embodiments of T7 variants according to the instant invention have a DNA-dependent RNA polymerase enzymatic activity and a reduced tendency to form intramolecular homodimers by way of oxidizing thiol groups. The amino acid substitutions within the T7 variants disclosed herein impact minimally, if at all, the RNA polymerase activity of the T7 polypeptide. Further, the mutations of the disclosed embodiments may optionally be combined with mutations which provide enhanced thermostability compared to the wild-type reference.
Abstract translation: 本公开提供了T7RNA聚合酶的新变体。 根据本发明的T7变体的实施方案包括T7多肽的氨基酸序列的位置723上的半胱氨酸 - 丝氨酸取代。 根据本发明的T7变体的实施方案具有DNA依赖性RNA聚合酶酶活性，并且通过氧化硫醇基形成分子内同型二聚体的趋势降低。 本文公开的T7变体内的氨基酸取代最小程度地影响T7多肽的RNA聚合酶活性。 此外，所公开的实施方案的突变可以任选地与与野生型参考物相比提供增强的热稳定性的突变组合。
-
Patent Agency Ranking
公开(公告)号：US11788108B2
公开(公告)日：2023-10-17
申请号：US17355962
申请日：2021-06-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Harald Sobek , Michael Greif , Marco Thomann , Sebastian Malik
CPC classification number: C12P21/005 , C07K16/00 , C12N9/1081 , C12P19/44 , C12Y204/99001 , C12Y301/03 , C07K2317/41
Abstract: The properties of certain glycosyltransferase variants having N-terminal truncation deletions or internal deletions are disclosed. Particularly, mutants that exhibit α-2,6-sialyltransferase enzymatic activity in the presence of CMP-activated sialic acid as co-substrate, and in the presence of a suitable acceptor site, are disclosed. A fundamental finding documented in the present disclosure is that enzymes are not only capable of catalyzing transfer of a sialidyl moiety but they are also capable of catalyzing hydrolytic cleavage of terminally bound sialic acid from a glycan.
-
公开(公告)号：US20140134633A1
公开(公告)日：2014-05-15
申请号：US14160453
申请日：2014-01-21
Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
Inventor： Ulrike Fischer , Michael Greif , Harald Sobek , Johann-Peter Thalhofer
IPC: C12Q1/68
CPC classification number: C12Q1/686 , C12N9/1252 , C12Q2527/137 , C12Q2521/101
Abstract: The present invention relates to a formulation of a thermostable DNA polymerase which is completely free of detergents and its particular use in real time polymerase chain reaction (PCR). Such a formulation may be obtained if the selected purification method does not require the addition of a detergent at any purification step.
Abstract translation: 本发明涉及完全不含洗涤剂的热稳定性DNA聚合酶的制剂及其在实时聚合酶链式反应（PCR）中的特别用途。 如果所选择的纯化方法不需要在任何纯化步骤中添加洗涤剂，则可以获得这样的制剂。
-
公开(公告)号：US11078511B2
公开(公告)日：2021-08-03
申请号：US15629040
申请日：2017-06-21
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Harald Sobek , Michael Greif , Marco Thomann , Sebastian Malik
Abstract: The present disclosure is directed to the properties of certain glycosyltransferase variants having N-terminal truncation deletions or internal deletions. Any of the mutants disclosed in here exhibit alpha-2,6-sialyltransferase enzymatic activity in the presence of CMP-activated sialic acid as co-substrate, and in the presence of a suitable acceptor site. A fundamental finding documented in the present disclosure is that these enzymes are not only capable of catalyzing transfer of a sialidyl moiety but they are also capable of catalyzing hydrolytic cleavage of terminally bound sialic acid from a glycan.
-
公开(公告)号：US10227642B2
公开(公告)日：2019-03-12
申请号：US14160453
申请日：2014-01-21
Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
Inventor： Ulrike Fischer , Michael Greif , Harald Sobek , Johann-Peter Thalhofer
Abstract: The present invention relates to a formulation of a thermostable DNA polymerase which is completely free of detergents and its particular use in real time polymerase chain reaction (PCR). Such a formulation may be obtained if the selected purification method does not require the addition of a detergent at any purification step.
-
公开(公告)号：US09809835B2
公开(公告)日：2017-11-07
申请号：US14950443
申请日：2015-11-24
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Alfred Engel , Michael Greif , Christine Jung , Sebastian Malik , Rainer Mueller , Harald Sobek , Bernhard Suppmann , Marco Thomann
CPC classification number: C12P19/18 , C12N9/1081 , C12P19/02 , C12P19/44 , C12P21/005
Abstract: The present disclosure is directed to the use of certain glycosyltransferase variants having N-terminal truncation deletions. Contrary to previous findings certain truncations were found to exhibit sialidase enzymatic activity, particularly a variant of human sialyltransferase (hST6Gal-I) with a truncation deletion involving the first 89 N-terminal amino acids of the respective wild-type polypeptide. A fundamental finding documented in the present disclosure is that there exists a variant of this enzyme which is capable of catalyzing transfer of a glycosyl moiety as well as hydrolysis thereof. Thus, disclosed is a specific exemplary variant of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variant of mammalian glycosyltransferase and use thereof, particularly for sialylating in a quantitatively controlled manner terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.03 seconds)
